---
title: Evaluation of Myocardial Perfusion Heterogeneity Imaging in Diabetes Patients (EVADIAB)
nct_id: NCT02316054
overall_status: COMPLETED
sponsor: University Hospital, Grenoble
study_type: OBSERVATIONAL
primary_condition: Type 2 Diabetes
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02316054.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02316054"
ct_last_update_post_date: 2016-12-07
last_seen_at: "2026-05-12T06:21:12.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of Myocardial Perfusion Heterogeneity Imaging in Diabetes Patients (EVADIAB)

**Official Title:** Long-term Additive Prognostic Value of Heterogeneity Myocardial Perfusion Imaging of SPECT Over Clinical and Ischemia in High-risk Diabetic Patients.

**NCT ID:** [NCT02316054](https://clinicaltrials.gov/study/NCT02316054)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 170
- **Lead Sponsor:** University Hospital, Grenoble
- **Conditions:** Type 2 Diabetes
- **Start Date:** 2007-11
- **Completion Date:** 2015-05
- **CT.gov Last Update:** 2016-12-07

## Brief Summary

Long-term additive prognostic value of heterogeneity myocardial perfusion imaging of SPECT over clinical and ischemia in high-risk diabetic patients

## Detailed Description

Currently, type II diabetes mellitus (DM), has reached epidemic levels in the world. Risk stratification is paramount in patients with DM due to not all patients with DM have a similar cardiovascular (CV) risk. Imaging has thus taken a central role in the assessment of CV health and in the diagnosis, evaluation, and management of CV diseases in DM. The prognostic value of relative myocardial perfusion imaging (MPI) using single-photon emission tomography (SPECT) is well established. Consistent with this data, DM patients with abnormal relative MPI results also have higher rates of death and non-fatal MI than those with normal results. However, DM patients with normal stress tests also have higher rates of cardiac events than non-DM counterparts with normal tests and despite that most guidelines recommend a systematic screening of asymptomatic high risk patients with diabetes for silent ischemia, real benefit of this strategy has not been demonstrated compared with optimal medical treatment without ischemia detection. New more sensitive noninvasive imaging to assess MPI abnormalities is needed.

Coronary microvascular dysfunction (CMVD) is closely associated with coronary artery disease; it is an independent risk factor and predicts future coronary events or clinically manifest disease up to 10 years later. To date, non-invasive measurement of CMVD myocardial perfusion heterogeneity imaging (MPHI) by SPECT is not available into clinical practice. We developed a new method to study the CMVD by SPECT. In this study, we use a mathematic technique from entropy analysis to provide precise, objective, automated quantification of MPHI at stress and at rest with SPECT. We sought to assess the prognostic value of MPHI in high-risk diabetic patients being investigated for ischemia. Therefore, we prospectively evaluated the incremental prognostic value of MPHI in patients with type 2 DM during long-term follow-up. Coronary microvascular dysfunction is closely associated with coronary artery disease; it is an independent risk factor and predicts future coronary events or clinically manifest disease up to 10 years later.

In this study, we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.

The main hypothesis is that the presence of myocardial perfusion heterogeneity is predictive of 5-year cardiovascular events in patients referred to the Nuclear Cardiology Department for routine evaluation of known or suspected CAD in diabetes patients with very high risk cardiovascular.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Type 2 diabetes mellitus
* Clinical indication for myocardial perfusion imaging
* Diabetics with very high risk of cardiovascular events defined by the SCORE risk

Exclusion Criteria:

* Pregnant woman
* Breast feeding women
* Severe comorbidity with life expectancy 6 months
```

## Arms

- **diabetes and MPHI** — myocardial perfusion heterogeneity imaging

## Interventions

- **MPHI** (DEVICE) — addictive value of MPHI to management of high risk cardiovascular type 2 diabetes

## Primary Outcomes

- **cardiac death,or Q-wave myocardial infarction (MI), or the need for myocardial revascularization > 3 months after SPECT** _(time frame: 4 years)_ — Composite outcome: cardiac death, Q-wave myocardial infarction (MI), the need for myocardial revascularization \> 3 months after SPECT

## Secondary Outcomes

- **cardiac death** _(time frame: 4 years)_
- **non fatal myocardial infarction** _(time frame: 4 years)_
- **myocardial revascularization > 3 months after SPECT** _(time frame: 2 years)_

## Locations (1)

- university Hospital, Grenoble, France

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital|grenoble||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02316054.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02316054*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*